tiprankstipranks
Solasia Pharma’s Strategic Progress in Global Markets
Company Announcements

Solasia Pharma’s Strategic Progress in Global Markets

Solasia Pharma KK (JP:4597) has released an update.

Don't Miss Our Christmas Offers:

Solasia Pharma K.K. has released its consolidated financial results for the second quarter of FY 2024, highlighting its strategic partnerships and progress in the commercialization of its pipeline products, Sancuso® and DARVIAS®. In China, after transferring sales functions to Lee’s Pharmaceutical, approval for a manufacturing facility change could reduce production costs, despite a temporary sales volume dip. DARVIAS® has received marketing approval in Japan and is preparing for regulatory approval in South America, with ongoing negotiations for out-licensing in China and a Named Patient Program facilitating access in other regions.

For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskSolasia Pharma Nears DARVIAS Licensing Deal in China
TipRanks Japan Auto-Generated NewsdeskSolasia Pharma K.K. Faces Revenue Decline
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App